-

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

New high-field NMR instrumentation strengthens biomolecular and materials science research at the UC Berkeley Pines Magnetic Resonance Center

BERKELEY, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley and Lawrence Berkeley National Laboratory.

The Pines Magnetic Resonance Center (PMRC) comprises faculty, technical staff, and postdoctoral researchers. The PMRC Core NMR facility is a leading shared NMR resource, offering 24/7 access to researchers from academia, national laboratories, and industry. By integrating high-performance instrumentation with method development, training, and analytical services, the facility enables multidisciplinary studies of molecular structure, dynamics, and function.

The investment is centered on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by several additional NMR systems and upgrades supporting solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research.

“This expansion will propel UC Berkeley, an institution with an exceptionally strong tradition in magnetic resonance, to the forefront of high-impact innovation for years to come,” said Professor Tatyana Polenova, Director of the Pines Magnetic Resonance Center. “By integrating next-generation NMR and DNP with advanced methodologies, including fast magic-angle spinning, MAS CryoProbes, computational analysis, and quantum sensing and control, we are opening new avenues to address previously inaccessible structural and mechanistic questions across a broad range of systems, including intact cells and organisms, macromolecular assemblies, bio-inspired materials, inorganic materials, and molecules at interfaces and surfaces.”

“Translating cutting-edge NMR technologies into robust, reproducible workflows is critical,” said Dr. Patrick Wikus, Head of Product Management at Bruker BioSpin. “The AV NEO-X platform provides a robust foundation for advanced solid-state, solution-state, and DNP NMR experiments, combining highest performance and enabling new capabilities with reliable day-to-day operation.”

The UC Berkeley NMR order exceeds $6 million and is expected to be delivered in 2027.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 978 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin Division
T: +49 172 3733531
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 978 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin Division
T: +49 172 3733531
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Reports Third Quarter 2026 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2026. Frank H. Laukien, Bruker’s President and CEO, commented: “Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successf...

Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A...

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

BERLIN--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei...
Back to Newsroom